帕博利珠单抗联合白蛋白结合型紫杉醇治疗早期三阴性乳腺癌患者——单臂II期试验(NeoImmunoboost,AGO-B-041)
NeoImmunoboost(AGO-B-041/NCT03289819)是一项多中心、前瞻性单臂II期试验,50例早期三阴性乳腺癌患者接受12周白蛋白结合型紫杉醇后接4周期表柔比星/环磷酰胺,帕博利珠单抗每3周联合给药。50例中33例(66.0%;95%CI 51.2%-78.8%)达到(ypT0/is ypN0)病理完全缓解,符合方案人群(n=39)为71.8%(95%CI 55.1%-85.0%)。作者认为该方案pCR率令人鼓舞、副作用可接受,在禁忌含铂化疗时可能是合理的替代选择,但无随机试验数据与长期随访,含铂/蒽环/紫杉类化疗仍是帕博利珠单抗的标准联合化疗。
要点
- 50例中33例达pCR(66.0%;95%CI 51.2%-78.8%),符合方案人群(n=39)pCR率71.8%(95%CI 55.1%-85.0%)
- 最常见任何级别不良事件为乏力(58.5%)、外周感觉神经病(54.7%)和中性粒细胞减少(52.8%)
- 作者认为在禁忌含铂化疗时该方案可能是合理替代,但含铂/蒽环/紫杉类仍是标准联合化疗
核心结论
- 白蛋白结合型紫杉醇联合蒽环类新辅助化疗并联合帕博利珠单抗的pCR率令人鼓舞,副作用可接受,在禁忌含铂化疗的情况下该治疗可能是合理的替代选择。
- 作者指出,在缺乏随机试验数据和长期随访的情况下,含铂/蒽环/紫杉类化疗仍是帕博利珠单抗的标准联合化疗。
研究设计与样本
- NeoImmunoboost(AGO-B-041/NCT03289819)是一项多中心、前瞻性单臂II期试验,计划入组50例患者。
- 患者接受12个每周周期的白蛋白结合型紫杉醇,随后接受4个每3周1次的表柔比星/环磷酰胺周期,帕博利珠单抗每3周与上述化疗联合给药。
- 在25例患者后,研究修订为在化疗前单次给予帕博利珠单抗。
- 主要终点为病理完全缓解(pCR),次要终点为安全性和生活质量。
主要发现
- 50例入组患者中33例(66.0%;95%CI 51.2%-78.8%)达到(ypT0/is ypN0)pCR。
- 符合方案人群(n=39)的pCR率为71.8%(95%CI 55.1%-85.0%)。
- 任何级别最常见不良事件为乏力(58.5%)、外周感觉神经病(54.7%)和中性粒细胞减少(52.8%)。
- 化疗前接受帕博利珠单抗剂量的27例患者队列pCR率为59.3%,未接受化疗前剂量的23例患者为73.9%。
临床怎么用
- 作者认为,在禁忌含铂化疗的情况下,白蛋白结合型紫杉醇联合蒽环类并联合帕博利珠单抗可能是合理的替代选择。
- 作者指出,在缺乏随机试验数据和长期随访的情况下,含铂/蒽环/紫杉类化疗仍是帕博利珠单抗的标准联合化疗。
局限性
- 作者指出,该结论缺乏随机试验数据和长期随访,含铂/蒽环/紫杉类化疗仍是帕博利珠单抗的标准联合化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab is approved for the neoadjuvant/adjuvant treatment of early triple-negative breast cancer (TNBC) patients in combination with chemotherapy. The Keynote-522 trial used platinum chemotherapy. As neoadjuvant nab-paclitaxel (nP) is also highly effective in triple-negative breast cancer patients, this study investigates the response to nP-containing neoadjuvant chemotherapy in combination with pembrolizumab. PATIENTS AND METHODS: NeoImmunoboost (AGO-B-041/NCT03289819) is a multicenter, prospective single-arm phase II trial. Patients were treated with 12 weekly cycles of nP followed by four three-weekly cycles of epirubicin/cyclophosphamide. Pembrolizumab was given three-weekly in combination with these chemotherapies. The study was planned for 50 patients. After 25 patients, the study was amended to include a pre-chemotherapy single application of pembrolizumab. The primary aim was pathological complete response (pCR), and the secondary aims were safety and quality of life. RESULTS: Of 50 included patients, 33 (66.0%; 95%confidence interval: 51.2%-78.8%) had a (ypT0/is ypN0) pCR. The pCR rate in the per-protocol population (n = 39) was 71.8% (95%confidence interval: 55.1%-85.0%). The most common adverse events of any grade were fatigue (58.5%), peripheral sensory neuropathy (54.7%) and neutropenia (52.8%). The pCR rate in the cohort of 27 patients with a pre-chemotherapy pembrolizumab dose was 59.3%, and 73.9% in the 23 patients without pre-chemotherapy dose. CONCLUSIONS: pCR rates after NACT with nP and anthracycline combined with pembrolizumab are encouraging. With acceptable side-effect profiles, this treatment might be a reasonable alternative to platinum-containing chemotherapy in cases of contraindications. However, without data from randomised trials and long-term follow up, platinum/anthracycline/taxane-based chemotherapy remains the standard combination chemotherapy for pembrolizumab.
引用
- Fasching PA, Hein A, Kolberg HC, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer. 2023. PMID: 36871424. doi:10.1016/j.ejca.2023.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。